Kura Oncology (KURA) Q4 2024 earnings summary

Executive summary

• Achieved positive Phase II results for ziftomenib in relapsed/refractory NPM1 mutant AML, supporting NDA submission in Q2 2025, and advanced programs in GIST, diabetes, and solid tumors.

• Strategic collaboration with Kyowa Kirin secured $330M upfront and up to $1.2B in milestones, funding development through potential commercialization.

• Multiple clinical milestones and data readouts for ziftomenib and pipeline programs expected throughout 2025.

Financial highlights

• Q4 2024 collaboration revenue was $53.9M, up from $0 in Q4 2023; cash, cash equivalents, and short-term investments totaled $727.4M at year-end 2024, including $330M from Kyowa Kirin.

• Q4 2024 R&D expenses were $52.3M (vs. $32.5M in Q4 2023); G&A expenses were $24.1M (vs. $14.2M in Q4 2023).

• Q4 2024 net loss was $19.2M, improved from $42.8M in Q4 2023; FY 2024 net loss was $174.0M (widened from $152.6M in 2023).

Outlook and guidance

• Cash position expected to fund operations into 2027 and support ziftomenib AML program through commercialization.

• NDA submission for ziftomenib in R/R NPM1-m AML anticipated in Q2 2025; multiple clinical data readouts and trial initiations expected in 2025.

• Top-line results for the KOMET-017 intensive frontline AML trial expected in 2028.